
Opinion|Videos|February 24, 2025
Oral Systemic Treatment Options for a 28-Year-Old Woman With Moderate Atopic Dermatitis
Author(s)Raj Chovatiya, MD, PhD, MSCI
The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.
Advertisement
Episodes in this series

Video content above is provided by the following:
- Please provide your initial impressions of this case. Does the involvement of the patient’s hands influence your management plan at all?
- How would you address the patient’s concerns regarding potential adverse effects of topical corticosteroids?
- Describe your approach to treatment options for this patient. What patient-specific factors would you take into consideration when deciding on a treatment?
- In what scenarios would a JAK inhibitor be preferred over another systemic agent?
- How would decide between a topical or systemic JAK inhibitor for a patient?
- What can the patient expect in terms of efficacy and safety with upadacitinib? When should she expect initial symptom relief?
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline
2
Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria
3
10 Skin Cancer Exam Tips
4
Dermatology Times Conferences & Meetings Calendar: September 2026
5






